Click here to read the Cover Story, “Treatment landscape for presbyopia evolving toward noninvasive options.”With the forthcoming FDA approval and commercialization of eye drops that improve near vision, the presbyopia market is on the cusp of a pharma…
Month: September 2021
Annual anti-inflammatory review
Sigh. Summertime in the northern latitudes is a fleeting joy.As you read this, Labor Day has come and gone. We celebrated my Mom, and the memory of my Dad, with a 30th consecutive White Family week on Cape Cod. It always seems like summer is over when …
Study Shows Heru’s Automated Visual Field Testing Platform Delivers Strong Correlation to Humphrey Field Analyzer
MIAMI–(BUSINESS WIRE)–A report by Heru Inc., the innovative vision diagnostics and augmentation leader, indicates that visual field test results from its wearable platform, re:Vive by Heru, are strongly correlated to the ZEISS Humphrey Field Analyzer…
Aerie executes succession plan to separate CEO, chairman roles
Benjamin F. McGraw III, PharmD, has been appointed as the interim executive chairman of the board of directors at Aerie Pharmaceuticals, replacing Vicente Anido Jr., PhD, the former chairman and CEO, according to a press release.“All of our employees a…
Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
2021 Report on Corneal Neovascularization Drugs In Development – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Corneal Neovascularization (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering. This report provides an overview of the Corneal Neovascularization (Ophthalmology) pipeli…
Cornea fellowship offers versatility for young ophthalmologists
A speaker at the Real World Ophthalmology meeting offered advice on how to be successful after finishing a cornea fellowship and beginning a career in practice.Nadia Haqqie, MD, said being a young physician can be difficult. Colleagues may send fairly …
15 million people may lose Medicaid coverage when public health emergency ends
A new report showed that about 15 million Americans who enrolled in Medicaid during the public health emergency could lose coverage when the emergency declaration ends.Those at risk for losing coverage include almost 9 million adults and 6 million chil…
Strong people skills, teamwork helpful for career in oculoplastics
The ideal oculoplastics fellowship candidate is a great ophthalmologist who can quickly build rapport with patients and develop unique ways to improve surgical and clinical care.“This is truly ideal for people who hear the call of the oculoplastics OR,…
Glaukos, Attillaps enter licensing agreement for Demodex-targeting therapies
Glaukos and Attillaps Holdings have entered into a licensing agreement that grants Glaukos a global exclusive license to Attillaps’ library of proprietary investigational compounds targeting Demodex mites, according to a press release.The agreement gra…
jCyte® Announces Appointment of Dr. Rebecca Kammer as Vice President of Clinical Operations
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced today the continued expansion of the Company’s leadership team with the appo…
Warby Parker Releases Financial Guidance for the Third Quarter and Fiscal Year 2021 and Fiscal Year 2022
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (the “Company”), a founder-led direct-to-consumer eyewear brand, today issued guidance for the third quarter ending September 30, 2021 and for the fiscal years ending December 31, 2021 and 2022. “As we look …
US Eye Adds New Partnerships in Virginia, North Carolina, South Carolina and Florida
SARASOTA, Fla.–(BUSINESS WIRE)– #Eyecare–US Eye, a physician-led network of patient-centric eye care practices, has expanded its practice base to 50 clinics and five surgery centers.
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective September 17, 2021, Vicen…
Aflibercept Matches Laser for Retinopathy of Prematurity
Aflibercept appears to work as well as laser photocoagulation for retinopathy of prematurity — at least in the short term. Medscape Medical News
Popular class of diabetes medications may be protective against glaucoma
A popular class of diabetes medications called GLP-1R agonists (Trulicity and Rybelsus) may also protect against glaucoma in diabetic patients, according to a new study led by researchers in the Scheie Eye Institute at the University of Pennsylvania’s …
3D Microscopy of Whole Organs with Micrometer Detail
A team of scientists at Umeå University in Sweden came up with a way to create complex 3D maps of whole organs in incredible detail. The approach involves embedding a whole organ in agarose, a stiff gel matrix, and then using this support matrix to section the tissue into cm3 chunks. These chunks are the […]
3D-Printed Origami Tube for Low-Cost Ventilators
Researchers at Simon Fraser University in Canada have developed a low-cost portable ventilator that uses a 3D-printed origami tube rather than a conventional airbag. The volume of the tube can be modified by changing the angles in the origami folding plates. As up to 95% of the components of the ventilator are 3D printable, the […]
FDA approves Byooviz, first ophthalmology biosimilar
The FDA has approved Byooviz as a biosimilar to Lucentis for the treatment of some retinal diseases and conditions, including wet age-related macular degeneration, according to a press release from Samsung Bioepis and Biogen.Byooviz (ranibizumab-nuna) …
FDA Approves Ranibizumab Biosimilar
Byooviz has the potential to be less expensive than Lucentis, the reference product. FDA Approvals